Genomic Cancer Panel and Profiling Market Report 2026

The genomic cancer panel and profiling market size has grown strongly in recent years. It will grow from $10.28 billion in 2025 to $11.17 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to growth in cancer prevalence, advancement in sequencing technologies, expansion of oncology diagnostics, increased funding for genomic research, rising adoption of precision medicine.

The genomic cancer panel and profiling market size is expected to see strong growth in the next few years. It will grow to $15.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to expansion of companion diagnostics, growth in liquid biopsy adoption, integration of ai in genomic analysis, increasing oncology screening programs, development of cost-effective sequencing platforms. Major trends in the forecast period include increasing adoption of multi-gene cancer panels, rising use of next-generation sequencing, expansion of liquid biopsy testing, growing demand for personalized oncology, integration of genomic data in clinical decision-making.

The increasing incidence of cancer is expected to drive the growth of the genomic cancer panel and profiling market going forward. Cancer is a disease marked by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer incidence is attributed to an aging population, as longer life expectancy increases the likelihood of developing cancer. Genomic cancer panels and profiling aid oncology care by identifying genetic mutations and biomarkers, enabling personalized treatment approaches, and improving early detection and disease monitoring. For instance, in January 2024, according to the American Cancer Society, a U.S.-based nonprofit organization, in 2022, approximately 20 million new cancer cases were reported worldwide, resulting in 9.7 million deaths; driven mainly by population growth, the global cancer burden is projected to reach 35 million cases by 2050. Therefore, the rising incidence of cancer is driving the growth of the genomic cancer panel and profiling market.

Major companies operating in the genomic cancer panel and profiling market are concentrating on technological advancements such as next-generation sequencers to enhance the accuracy, speed, and depth of cancer diagnostics and support more personalized treatment decisions. Next-generation sequencers are advanced DNA sequencing technologies that allow rapid, high-throughput analysis of genetic material to detect mutations, variations, and other genomic characteristics. For instance, in April 2025, QIAGEN N.V., a Netherlands-based biotechnology company, launched QIAseq panels developed for next-generation sequencers, enabling comprehensive genomic profiling through the analysis of more than 700 genes. These panels are designed for both research and clinical use, with the objective of improving cancer diagnostics and treatment approaches.

In June 2023, Quest Diagnostics, a US-based clinical laboratory company, acquired Haystack Oncology for an undisclosed amount. Through this acquisition, Quest Diagnostics expanded its capabilities in liquid biopsy and cancer detection, strengthening its genomic testing portfolio. Haystack Oncology is a US-based biotechnology company focused on developing innovative liquid biopsy technologies for early cancer detection and disease monitoring.

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

North America was the largest region in the genomic cancer panel and profiling market in 2025. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomic cancer panel and profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the genomic cancer panel and profiling market by increasing the cost of imported sequencing instruments, reagents, and diagnostic consumables. These impacts have been most significant in hospital and diagnostic laboratory segments in North America and Europe. Asia-Pacific regions have experienced cost pressures due to reliance on imported genomic technologies. However, tariffs have encouraged local manufacturing of diagnostic kits and strengthened regional genomic testing capabilities.

The genomic cancer panel and profiling market research report is one of a series of new reports that provides genomic cancer panel and profiling market statistics, including genomic cancer panel and profiling industry global market size, regional shares, competitors with a genomic cancer panel and profiling market share, detailed genomic cancer panel and profiling market segments, market trends and opportunities, and any further data you may need to thrive in the genomic cancer panel and profiling industry. This genomic cancer panel and profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genomic cancer panel and profiling is a molecular diagnostic approach that examines multiple genes at the same time to identify genetic mutations, alterations, or biomarkers linked to cancer. Its main objective is to support personalized treatment decisions, predict disease progression, and enhance cancer diagnosis and monitoring.

The main tissue testing types in genomic cancer panel and profiling include solid tissue testing and liquid tissue testing. Solid tissue testing involves analyzing samples obtained from solid tumors or organs to detect genetic mutations, biomarkers, or disease-specific characteristics. This process utilizes technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and others, and includes both single-gene and multi-gene cancer panels. These tests are applied in clinical and research settings and are used by hospitals, research and academic institutes, clinical and diagnostic laboratories, and other end users.

The genomic cancer panel and profiling market consists of revenues earned by entities by providing services such as genetic mutation analysis, companion diagnostic testing, cancer risk assessment, and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic cancer panel and profiling market also includes sales of targeted gene panels, companion diagnostic kits, sequencing platforms and instruments, bioinformatics software, and analysis tools. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.